Prospective Surveillance of Antiviral Resistance in Hospitalized Infants Less than 12 Months of Age with A(H3N2) Influenza Infection and Treated with Oseltamivir
Free accessResearch articleFirst published online August, 2017
Prospective Surveillance of Antiviral Resistance in Hospitalized Infants Less than 12 Months of Age with A(H3N2) Influenza Infection and Treated with Oseltamivir
Infants exhibit elevated influenza virus loads and prolonged viral shedding, which may increase the risk for resistance development, especially in cases of suboptimal exposure to antiviral therapy.
Methods
We performed a prospective surveillance of hospitalized infants undergoing oseltamivir therapy during the 2008–2009 and 2011–2012 influenza seasons at two paediatric hospitals in Germany. A total of 37 infants less than 1 year of age with laboratory confirmed influenza A(H3N2) infection received oseltamivir as per physician's order for 5 days (2008–2009 season: 2 mg/kg twice daily; 2011–2012 season: 2.0 mg/kg; 2.5 mg/kg and 3.0 mg/kg twice daily for infants <1 month; 2–3 months and 4–12 months, respectively). Virus load, the susceptibility to neuraminidase inhibitors (NAIs), and the presence of molecular markers of resistance to NAIs was assessed for influenza viruses recovered from respiratory samples collected at baseline and during follow-up visits.
Results
Overall, 73% of the infants continued to shed viral RNA detectable by reverse transcription (RT)-PCR after dose number 10 of oseltamivir; 12 infants shed viruses, 2 of them (both 9 months of age) shed resistant viruses. Resistance was characterized by ≥1,000-fold increase of 50% inhibitory concentration (IC50) for oseltamivir, up to 50-fold for zanamivir and elevated Km values when compared to susceptible A(H3N2) strains. Sanger sequencing revealed the selection of the NA-R292K substitution in both instances (after dose number 10 on day 6).
Conclusions
Our data suggest that it may be relevant to monitor antiviral resistance systematically in all infants, considering that the European Medicines Agency has recently extended the licensure for oseltamivir to include full-term infants.
KamalM.A., AcostaE.P., KimberlinD.W.The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach.Clin Pharmacol Ther2014; 96: 380–389.
6.
RathB.A., BrzostekJ., GuillenS.Safety, virology and pharmacokinetics of oseltamivir in infants with laboratory-confirmed influenza: a Phase I/II, prospective, open-label, multicentre clinical trial.Antivir Ther2015; 20: 815–825.
7.
LouieJ.K., YangS., SamuelM.C., UyekiT.M., SchechterR.Neuraminidase inhibitors for critically ill children with influenza.Pediatrics2013; 132: e1539–e1545.
8.
StrengA., GroteV., LieseJ.G.Severe influenza cases in paediatric intensive care units in Germany during the pre-pandemic seasons 2005 to 2008.BMC Infect Dis2011; 11: 233.
9.
BhatN., WrightJ.G., BroderK.R.Influenza-associated deaths among children in the United States, 2003-2004.N Engl J Med2005; 353: 2559–2567.
10.
RathB., von KleistM., TiefF.Virus load kinetics and resistance development during oseltamivir treatment in infants and children infected with Influenza A(H1N1) 2009 and influenza B viruses.Pediatr Infect Dis J2012; 31: 899–905.
11.
KimberlinD.W., AcostaE.P., PrichardM.N.Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza.J Infect Dis2013; 207: 709–720.
12.
TamuraD., SugayaN., OzawaM.Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors.Clin Infect Dis2011; 52: 432–437.
13.
FraaijP.L., SchuttenM., JavouheyE.Viral shedding and susceptibility to oseltamivir in hospitalized immunocompromised patients with influenza in the Influenza Resistance Information Study (IRIS).Antivir Ther2015; 20: 633–642.
14.
HurtA.C., BesselaarT.G., DanielsR.S.Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015.Antiviral Res2016; 132: 178–185.
15.
MeijerA., Rebelo-de-AndradeH., CorreiaV.Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013.Antiviral Res2014; 110: 31–41.
16.
TakashitaE., MeijerA., LackenbyA.Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014.Antiviral Res2015; 117: 27–38.
17.
HurtA.C.The epidemiology and spread of drug resistant human influenza viruses.Curr Opin Virol2014; 8: 22–29.
18.
HurtA.C., LeangS.K., TiedemannK.Progressive emergence of an oseltamivir-resistant A(H3N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patient.Influenza Other Respir Viruses2013; 7: 904–908.
19.
PirallaA., Gozalo-MarguelloM., FiorinaL.Different drug-resistant influenza A(H3N2) variants in two immunocompromised patients treated with oseltamivir during the 2011-2012 influenza season in Italy.J Clin Virol2013; 58: 132–137.
20.
WhitleyR.J., BoucherC.A., LinaB.Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS).Clin Infect Dis2013; 56: 1197–1205.
21.
KisoM., MitamuraK., Sakai-TagawaY.Resistant influenza A viruses in children treated with oseltamivir: descriptive study.Lancet2004; 364: 759–765.
22.
StephensonI., DemocratisJ., LackenbyA.Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.Clin Infect Dis2009; 48: 389–396.
23.
SugayaN., Sakai-TagawaY., BambaM.Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.Antivir Ther2015; 20: 49–55.
24.
RathB., TiefF., KarschK.Towards a personalised approach to managing influenza infections in infants and children - food for thought and a note on oseltamivir.Infect Disord Drug Targets2013; 13: 25–33.
25.
RathB., TiefF., ObermeierP.Early detection of influenza A and B infection in infants and children using conventional and fluorescence-based rapid testing.J Clin Virol2012; 55: 329–333.
26.
SiedlerK., SkopnikH.Oseltamivir for treatment of influenza in infants less than one year: a retrospective analysis.Pediatr Infect Dis J2010; 29: 495–498.
SchulzeM., NitscheA., SchweigerB., BiereB.Diagnostic approach for the differentiation of the pandemic influenza A(H1N1)v virus from recent human influenza viruses by real-time PCR.PLoS One2010; 5: e9966.
29.
ChenX., Pouran YousefK., DuweS.Quantitative influenza follow-up testing (QIFT)–a novel biomarker for the monitoring of disease activity at the point-of-care.PLoS One2014; 9: e92500.
30.
MatrosovichM., MatrosovichT., CarrJ., RobertsN.A., KlenkH.D.Overexpression of the -2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors.J Virol2003; 77: 8418–8425.
31.
WHO.Global, Influenza, Surveillance, Network. Manual for the laboratory diagnosis and virological surveillance of influenza Switzerland; 2011. (Accessed 25 November 2015.) Available from whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf.
32.
PotierM., MameliL., BelisleM., DallaireL., MelanconS.B.Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate.Anal Biochem1979; 94: 287–296.
33.
DuweS., SchweigerB.A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1.J Virol Methods2008; 153: 134–141.
34.
WHO.Meetings of the WHO working group on surveillance of influenza antiviral susceptibility- Geneva, November 2011 and June 2012. (Accessed 25 November 2015.) Available from http://www.who.int/wer/2012/wer8739.pdf.
35.
NguyenH.T., FryA.M., GubarevaL.V.Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.Antivir Ther2012; 17: 159–173.
RathB.A., BlumentalsW.A., MillerM.K., StarzykK., TetiurkaB., WollenhauptM.A prospective observational study of oseltamivir safety and tolerability in infants and young children </=24 months.Pharmacoepidemiol Drug Saf2015; 24: 286–296.
38.
WattanagoonY., StepniewskaK., LindegardhN.Pharmacokinetics of high-dose oseltamivir in healthy volunteers.Antimicrob Agents Chemother2009; 53: 945–952.
HerlocherM.L., TrusconR., EliasS.Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets.J Infect Dis2004; 190: 1627–1630.
41.
YenH.L., HerlocherL.M., HoffmannE.Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.Antimicrob Agents Chemother2005; 49: 4075–4084.
42.
CarrJ., IvesJ., KellyL.Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo.Antiviral Res2002; 54: 79–88.
43.
McKimm-BreschkinJ.L.Resistance of influenza viruses to neuraminidase inhibitors–a review.Antiviral Res2000; 47: 1–17.
44.
WagnerR., MatrosovichM., KlenkH.D.Functional balance between haemagglutinin and neuraminidase in influenza virus infections.Rev Med Virol2002; 12: 159–166.
45.
McKimm-BreschkinJ.L., SahasrabudheA., BlickT.J.Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors.J Virol1998; 72: 2456–2462.
46.
BlickT.J., SahasrabudheA., McDonaldM.The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en.Virology1998; 246: 95–103.
47.
LeeH.K., TangJ.W., LohT.P.Emergence of G186D mutation in the presence of R292K mutation in an immunocompromised child infected with influenza A/H3N2 virus, treated with oseltamivir.J Clin Microbiol2014; 52: 1749–1750.
48.
AbedY., BourgaultA.M., FentonR.J.Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene.J Infect Dis2002; 186: 1074–1080.
49.
IsonM.G., GubarevaL.V., AtmarR.L., TreanorJ., HaydenF.G.Recovery of drug-resistant influenza virus from immunocompromised patients: a case series.J Infect Dis2006; 193: 760–764.
50.
MatrosovichM., TuzikovA., BovinN.Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals.J Virol2000; 74: 8502–8512.
51.
BloomJ.D., GongL.I., BaltimoreD.Permissive secondary mutations enable the evolution of influenza oseltamivir resistance.Science2010; 328: 1272–1275.
52.
ButlerJ., HooperK.A., PetrieS.Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses.PLoS Pathog2014; 10: e1004065.
